Stockscreener 앱 받기
5.94
1.98%
-0.12
시간 외 거래:
5.93
-0.01
-0.17%
전일 마감가:
$6.06
열려 있는:
$6.1
하루 거래량:
125.88K
Relative Volume:
1.26
시가총액:
$576.35M
수익:
$116.59M
순이익/손실:
$9.88M
주가수익비율:
264.00
EPS:
0.0225
순현금흐름:
$-2.40M
1주 성능:
-5.11%
1개월 성능:
-20.16%
6개월 성능:
-24.33%
1년 성능:
-31.57%
1일 변동 폭
$5.87
$6.16
1주일 범위
$5.87
$6.2935
52주 변동 폭
$5.87
$11.61
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(858) 284-0115
주소
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
5.94 | 587.99M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | Jefferies | Buy |
| 2025-08-26 | 개시 | H.C. Wainwright | Buy |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Stage - Newser
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale - Investing.com
GYRE (GYRE) COO sells 22,220 shares after stock option exercises - Stock Titan
GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill
Gyre Therapeutics (GYRE) director cancels 250,000-share stock option agreement - Stock Titan
Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares - Investing.com
Gyre Therapeutics (GYRE) COO sells shares after exercising options - Stock Titan
Gyre Therapeutics (GYRE) Stock: Slides -2.17%, Support at $5.98 2026-05-19Advance Decline Volume - Newser
GYRE (GYRE) COO Ye exercises options and sells 28,680 shares in May - Stock Titan
Gyre Therapeutics (GYRE) Fell -6.43% — Is a Recovery Ahead? 2026-05-17Community Momentum Stocks - Newser
Gyre Therapeutics and Cullgen Advance CDK2-Cyclin E Degrader CG923308 for Treatment of Solid Tumors and CDK4/6i-Resistant Breast Cancer - Minichart
GYRE Should I Buy - Intellectia AI
Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion - TipRanks
Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027 - TradingView
Gyre Therapeutics (NASDAQ: GYRE) showcases degrader pipeline and CG923308 IND plans - Stock Titan
Gyre Therapeutics stock (KYG4200L1031): Low short interest signals stability amid pharma peers - AD HOC NEWS
China regulator accepts Gyre’s liver fibrosis drug application By Investing.com - Investing.com India
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (Hydronidone) to Treat CHB-Induced Liver Fibrosis - Minichart
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics’ F351 NDA Accepted for Priority Review - TipRanks
Gyre Therapeutics announces NMPA acceptance of new drug application for F351 (hydronidone) - marketscreener.com
Gyre Therapeutics (GYRE) wins NMPA review acceptance for F351 liver fibrosis NDA - Stock Titan
GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition - TipRanks
China regulator accepts Gyre’s liver fibrosis drug application - Investing.com India
New hepatitis B liver drug for China’s tens of millions enters NMPA review - Stock Titan
TradingKey - TradingKey
Number of shareholders of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
[144] GYRE THERAPEUTICS, INC. SEC Filing - Stock Titan
Q2 EPS Forecast for Gyre Therapeutics Reduced by Analyst - MarketBeat
Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics, Inc. 10-Q Quarterly Financial Report March 31, 2026 – Financial Statements, Risk Factors, and Disclosures - Minichart
Gyre Therapeutics (NASDAQ: GYRE) Q1 2026 results and $300M Cullgen deal - Stock Titan
Gyre Therapeutics stock (KY.G4200L1031): Acquisition of Cullgen and Q1 2026 results in focus - AD HOC NEWS
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss - TipRanks
Gyre Therapeutics CEO Luo Ying sells $82,927 in company stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics CEO Luo Ying sells $82,927 in company stock - Investing.com India
Gyre Therapeutics (GYRE) CEO spouse sells 10,315 shares under plan - Stock Titan
Gyre Therapeutics (GYRE) CSO discloses new Series B stake - Stock Titan
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
GYRE STOCK ALERT: Kaskela Law Firm Announces Shareholder Investigation into Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) reports Q1 loss, lags revenue estimates - MSN
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (GYRE) Gyre Therapeutics, Inc. Reports Q1 Revenue $22.5M, vs. FactSet Est of $31.6M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q1 Loss $0.10 a Share, vs. FactSet Est of $0.07 Loss - marketscreener.com
Q1 2026 loss and Cullgen deal reshape Gyre Therapeutics (NASDAQ: GYRE) - Stock Titan
Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates - TradingView
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Gyre Therapeutics Inc 주식 (GYRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer |
May 20 '26 |
Option Exercise |
0.75 |
9,400 |
7,050 |
709,400 |
| Ye Weiguo | Chief Operating Officer |
May 21 '26 |
Sale |
6.15 |
12,820 |
78,843 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 20 '26 |
Sale |
6.15 |
9,400 |
57,810 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 19 '26 |
Option Exercise |
0.75 |
9,120 |
6,840 |
709,120 |
| Ye Weiguo | Chief Operating Officer |
May 18 '26 |
Option Exercise |
0.75 |
200 |
150 |
700,200 |
| Ye Weiguo | Chief Operating Officer |
May 19 '26 |
Sale |
6.37 |
9,120 |
58,094 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 18 '26 |
Sale |
6.62 |
200 |
1,324 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 14 '26 |
Option Exercise |
0.75 |
15,580 |
11,685 |
715,580 |
| Ye Weiguo | Chief Operating Officer |
May 15 '26 |
Option Exercise |
0.75 |
13,100 |
9,825 |
713,100 |
| Ye Weiguo | Chief Operating Officer |
May 14 '26 |
Sale |
6.91 |
15,580 |
107,658 |
700,000 |
0.98%
0.12%
자본화:
|
볼륨(24시간):